World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Tel. direct: +41 22 791 46 27
Fax direct: +41 22 791 47 30
Email: prequalinspection@who.int

In reply please refer to: P5-447-3/DC/SC/1

Your reference:

Dr Kamal Vashi
Mangalam Drugs and Organics Ltd
Unit 1
Plot No 187, 2nd Phase GIDC, Vapi
Gujarat, 396 195 Dist. Valsad Gujarat
Inde

14 April 2023

Dear Dr Vashi,

WHO Prequalification Unit – Inspection Services
Closing of Inspection: Mangalam Drugs and Organics Ltd Unit-1

I refer to the inspection that was performed by Dr Catsoulacos and Dr Dimas the details of which are outlined below:

Name:	Mangalam Drugs and Organics Ltd, Unit 1
Address:	Plot No 187, 2nd Phase GIDC, Vapi Gujarat, 396 195, Dist. Valsad, India
Date:	21-24 June 2022

Thank you for your correspondence dated 5 August and 16 December 2022 and the corrective actions to the observations listed in the inspection report. The actions taken, or proposed to be taken, to correct the deficiencies have been reviewed by the inspectors.

In general, they are considered acceptable and their satisfactory implementation will be verified during future inspections. On the basis of the findings of the inspection and these subsequent responses the inspectors have recommended that the APIs:

- APIMF 100 Lumefantrine
- APIMF 138 Artemether
- APIMF 134 Amodiaquine Hydrochloride
- APIMF 135 Artesunate
- APIMF 149 Piperaquine Phosphate
- APIMF 151 Dihydroartemisinin
- APIMF 204 Tenofovir Disoproxil Fumarate
- APIMF 356 Sulfadoxine
- APIMF 380 Primaquine Phosphate

are considered to be compliant with the standards of Good Manufacturing Practices (GMP) for APIs published by the World Health Organization (WHO), for the scope of activities listed below:

- Manufacture and packaging of APIs.
- Analytical and microbiological testing of raw materials and associated intermediates and API.

Furthermore, the inspection findings and your response allow us to recommend to the Prequalification Assessment Group that the site inspected may be named as API manufacturing site in dossiers assessed within the WHO Prequalification Unit.

Please note that acceptance of compliance with WHO GMP does not necessarily mean that the API product has been prequalified by WHO. You will be notified of the outcome of the assessment of your prequalification application in due course.

Please do not hesitate to send an email to **prequalinspection@who.int** should you require any further information regarding the closing of this inspection.

Yours sincerely,

Mr Deus Mubangizi
Unit Head
Prequalification Unit

Acting Team Lead, Inspection Services
Regulation and Prequalification Department
Access to Medicines and Health Products Division